Option chain shows key data for NLS Pharmaceutics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for NLS Pharmaceutics.

NLS Pharmaceutics (NASDAQ:NLSP) Stock, Option Chain

NLS Pharmaceutics

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

Why It Matters

News

Movers

NLSP

NLS Pharmaceutics shares are trading higher on Monday after the company announced it secured up to $3 million in equity financing.

What&#39;s Going On With NLS Pharmaceutics Shares Monday?

Lattice Semiconductor

Pre-Market Outlook

Markets

Trading Ideas

ACLS

AMKR

BHAT

BNAI

FLNC

GNPX

HLIT

LIXT

LSCC

OCEA

PRLD

SGRY

SLQT

SLXN

TANH

VSTE

Why Lattice Semiconductor Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

Wall Street_Dow

Earnings

Equities

Eurozone

Commodities

Intraday Update

ENVB

NIVF

VIAV

Dow Edges Lower; Exxon Mobil Earnings Top Views

NLS Pharmaceutics Ltd

Small Cap

Press Releases

NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting

Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics

NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment

NLS Pharmaceutics Announces New Preclinical Data for AEX-2, Expanding the Therapeutic Potential of its Non-Sulfonamide Dual Orexin Receptor Agonist Platform

NLS Pharmaceutics CEO Issues Letter to Shareholders

Offerings

NLS Pharmaceutics and Kadimastem Announces Up to $3 Million Equity Financing and $25 Million Equity Facility Agreement

NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

KMSTF

NLSPW

Laidlaw & Co.

Comments

NLS Pharmaceutics

NLS Pharmaceutics (NLSP) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga